医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

DNAnexus Platform Powers Garvan Institute’s Move to Provide Global Genomic Sequencing Services

2015年02月23日 PM10:00
このエントリーをはてなブックマークに追加


 

MOUNTAIN VIEW, Calif.

DNAnexus Inc., a pioneer in cloud-based genome informatics and data management, today announced that the Garvan Institute of Medical Research in Sydney, Australia is now using DNAnexus as the bioinformatics platform underlying many of its genomics-based research initiatives. The Institute will also utilize DNAnexus to support its push to offer commercial genome sequencing services.

When the Garvan Institute and its Kinghorn Centre for Clinical Genomics (KCCG) obtained the means to conduct large-scale whole human genome sequencing recently, it came with a petabyte-sized caveat – a pressing need to manage, analyze, and secure massive quantities of data. Using the DNAnexus platform, the Institute is able to meet those needs without the time and capital expenditures of building out their local infrastructure. Activities on the DNAnexus platform range from high-speed, cost-efficient delivery of sequence data to streamlined collaborations involving complex genomics analyses carried out between Garvan and their worldwide research partners.

“With the help of the DNAnexus platform, we have deployed a service that capitalizes on lower costs of whole genome sequencing,” according to Marcel Dinger, head of KCCG. “We want to make that data available and actionable worldwide, whether in a research, commercial, or clinical setting.”

KCCG now has the capability to sequence 150 whole human genomes every three days, which amounts to 18,000 sequences per annum.

“The Garvan Institute of Medical Research is now producing an unprecedented amount of bioinformatics data that they want to share with their worldwide customers and partners,” according to Richard Daly, CEO of DNAnexus. “We are proud to support the expansion of Garvan’s sequencing services, and help them manage and benefit from the flood of genomic data they now have at their disposal.”

About DNAnexus

DNAnexus provides a global network for genomic data management to accelerate genomic medicine. The DNAnexus cloud-based platform is optimized to address the challenges of security, scalability, and collaboration, for organizations that are pursuing genomic-based approaches to health, in the clinic and in the research lab. The DNAnexus team is made up of experts in computational biology and cloud computing who work with organizations to tackle some of the most exciting opportunities in human health, making it easier—and in many cases feasible—to work with genomic data. With DNAnexus, organizations can stay a step ahead in leveraging genomics to achieve their goals. The future of human health is in genomics. DNAnexus brings it all together. For more information please visit: https://dnanexus.com or follow us on Twitter @dnanexus

About the Garvan Institute for Medical Research

The Garvan Institute of Medical Research was founded in 1963 and is now one of Australia’s largest medical research institutions with over 600 scientists, students and support staff. Garvan’s main research areas are: Cancer, Diabetes & Metabolism, Immunology and Inflammation, Osteoporosis and Bone Biology, and Neuroscience. Garvan’s mission is to make significant contributions to medical science that will change the directions of science and medicine and have major impacts on human health. The outcome of Garvan’s discoveries is the development of better methods of diagnosis, treatment, and ultimately, prevention of disease.

In 2012, Garvan established Australia’s first purpose-built facility for undertaking large-scale research projects and clinical-grade genome sequencing. The Kinghorn Centre for Clinical Genomics (KCCG) researchers undertake collaborative projects and genome-based studies to improve genome interpretation, with the ultimate aim of advancing the use of genomic information in patient care. KCCG is seeking accreditation that would ultimately allow clinicians to sequence genomes for diagnostic and therapeutic purposes. For more information about KCCG, see http://www.garvan.org.au/research/clinical-genomics and follow us on Twitter @kinghorngenomes.

CONTACT

For Garvan Institute
Alison Heather, +61 (0) 2 9295 8128 (T) or +61
(0) 434 071 326 (M)
Science Communications Manager
a.heather@garvan.org.au
or
For
DNAnexus
Tim Smith, 415-350-3019
Element Public Relations
tsmith@elementpr.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent